100 results on '"Bhasin, Manoj K."'
Search Results
2. Early Injury Landscape in Vein Harvest by Single-Cell and Spatial Transcriptomics
3. The Simple prEservatioN of Single cElls method for cryopreservation enables the generation of single-cell immune profiles from whole blood
4. Integrated single-nuclei and spatial transcriptomic analysis reveals propagation of early acute vein harvest and distension injury signaling pathways following arterial implantation
5. Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial
6. Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape
7. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis
8. DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway
9. Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
10. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
11. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
12. Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
13. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
14. Supplementary Figure FS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
15. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
16. Supplementary Figure FS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
17. Supplementary Figure 3 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
18. Supplementary Figure 7 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
19. Supplementary Figure 5 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
20. Supplementary Figure 6 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
21. Supplementary Figure 8 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
22. Supplementary Table 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
23. Supplementary Figure Legends from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
24. Data from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
25. Supplementary Figure 5 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
26. Supplementary Figure 7 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
27. Supplementary Figure 2 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
28. Supplementary Figure 9 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
29. Supplementary Figure 3 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
30. Supplementary Figure 2 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
31. Supplementary Figure 9 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
32. Supplementary Figure Legends from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
33. Supplementary Figure 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
34. Data from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
35. Supplementary Figure 4 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
36. Supplementary Figure 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
37. Supplementary Methods from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
38. Supplementary Table 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
39. Supplementary Figure 6 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
40. Supplementary Figure 4 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
41. Supplementary Methods from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
42. Supplementary Figure 8 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
43. Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
44. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
45. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
46. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
47. Supplementary Figure from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
48. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
49. Supplementary Figure from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
50. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.